BACKGROUND: Except for a documented increase in osteoprotegerin (OPG) concentrations with older age, data on determinants of soluble Receptor Activator of Nuclear Factor κB (sRANKL) and OPG concentrations in women are limited. We evaluated reproductive and lifestyle factors as potential sources of variation in circulating sRANKL and OPG concentrations in pre- and postmenopausal women. METHODS: This study includes 2016 controls (n=1552 (76%) postmenopausal, n=757 (38%) using postmenopausal hormone therapy (PMH)) from a breast cancer case-control study nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Serum sRANKL was measured using an enzyme-linked immunosorbent assay, serum OPG using an electrochemilu...
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary t...
Objective: The aim of this study was to investigate the correlations among circulating osteoproteger...
PurposeThe osteoprotogerin/receptor activator of NF-kappa β/receptor activator of NF-kappa β ligand ...
BACKGROUND: Except for a documented increase in osteoprotegerin (OPG) concentrations with older age,...
Except for a documented increase in osteoprotegerin (OPG) concentrations with older age, data on det...
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary t...
Background: Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growt...
BACKGROUND: Breast cancer risk for postmenopausal women is positively associated with circulating co...
Funding Information: The study was supported by grants and fellowships from Stiftelsen Kristian Gerh...
Background: Breast cancer risk for postmenopausal women is positively associated with circulating co...
Background: Breast cancer risk for postmenopausal women is positively associated with circulating co...
Abstract OBJECTIVE: The aim of this study was to investigate the correlations among circulating ...
BACKGROUND: Breast cancer risk for postmenopausal women is positively associated with circulating co...
Background: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor ...
BACKGROUND: Breast cancer risk for postmenopausal women is positively associated with circulating co...
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary t...
Objective: The aim of this study was to investigate the correlations among circulating osteoproteger...
PurposeThe osteoprotogerin/receptor activator of NF-kappa β/receptor activator of NF-kappa β ligand ...
BACKGROUND: Except for a documented increase in osteoprotegerin (OPG) concentrations with older age,...
Except for a documented increase in osteoprotegerin (OPG) concentrations with older age, data on det...
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary t...
Background: Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growt...
BACKGROUND: Breast cancer risk for postmenopausal women is positively associated with circulating co...
Funding Information: The study was supported by grants and fellowships from Stiftelsen Kristian Gerh...
Background: Breast cancer risk for postmenopausal women is positively associated with circulating co...
Background: Breast cancer risk for postmenopausal women is positively associated with circulating co...
Abstract OBJECTIVE: The aim of this study was to investigate the correlations among circulating ...
BACKGROUND: Breast cancer risk for postmenopausal women is positively associated with circulating co...
Background: Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor ...
BACKGROUND: Breast cancer risk for postmenopausal women is positively associated with circulating co...
Receptor activator of nuclear factor-kappa B (RANK)-RANK ligand (RANKL) signaling promotes mammary t...
Objective: The aim of this study was to investigate the correlations among circulating osteoproteger...
PurposeThe osteoprotogerin/receptor activator of NF-kappa β/receptor activator of NF-kappa β ligand ...